Completed
PHASE1
INTERVENTIONAL
NCT06003465
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to look at the amount of the study drug, LY3437943, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of LY3437943 and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 16 weeks, including screening.
Interventions
Name:
LY3437943
Type:
DRUG
Description:
Administered SC
Name:
Test
Type:
DEVICE
Description:
Used to administer LY3437943 SC
Name:
Reference
Type:
DEVICE
Description:
Used to administer LY3437943 SC
Primary Outcomes
Measure:
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943
TimeFrame:
Predose up to 43 days postdose
Description:
PK: Cmax of LY3437943
Measure:
PK: Area Under the Plasma Concentration Versus Time Curve from Zero to T, Last Time Point (AUC[0-tlast]) of LY3437943
TimeFrame:
Predose up to 43 days postdose
Description:
PK: AUC\[0-tlast\] of LY3437943
Measure:
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943
TimeFrame:
Predose up to 43 days postdose
Description:
PK: AUC(0-∞) of LY3437943
Trial Information
NCT ID
NCT06003465
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025